0

Aduro Biotech Fails Phase 2 Pancreatic Cancer; Shares Fall 16%

Shares of Aduro Biotech (NASDAQ:ADRO) tanked by 16.65% today after the company announced that it had failed its phase 2b “Eclipse” trial in patients with pancreatic cancer. The phase 2b trial was testing the company’s vaccine immunotherapy CRS-207, which is… Continue Reading

0

Rxi Pharmaceuticals Obtains Partnership Agreement For ALS With Thera Neuropharma

On Tuesday May 3, 2016 Rxi Pharmaceuticals (NASDAQ:RXII) announced that it has entered into a license agreement with a privately-held pharmaceutical company known as Thera NeuroPharma. The license agreement expands on the notion that Thera NeuroPharma will use Rxi’s sd-rxRNA… Continue Reading

0

Sarepta’s Eteplirsen Gets Thumbs Down Votes By FDA Advisory Panel

On Monday, an FDA Advisory panel voted down Sarepta Therapeutics (NASDAQ:SRPT) Eteplirsen to treat patients with Duchenne Muscular Dystrophy or DMD. The panel noted concerns with the fact that only 12 patients were recruited in the trial. The truth is that… Continue Reading

0

RXi Pharmaceuticals Patent And Conference Call News Update

On Thursday RXi Pharmaceuticals (NASDAQ:RXII) announced that it had received a patent from the United States Patent and Trademark Office — USPTO — for a patent that covers RXi’s technology sd-rxRNA along with Connective Tissue Growth Factor — CTGF. The patent… Continue Reading